arrow
J

Jules A. A. C. Heuberger

Centre for Human Drug Research
H指数:20
被引数:1,403

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sustained pharmacodynamic effects of S-ketamine on cortical excitability and resting-state brain activity: A randomized, placebo-controlled trial

S-氯胺酮对皮层兴奋性和静息态脑活动持续药效作用的随机、安慰剂对照试验

2026-06-240
OAAI
Transcranial Magnetic Stimulation as a Translational Biomarker in Early-Phase Anti-Seizure Medication Development: A Randomized, Double-Blind, Placebo-Controlled Study in Generalized Epilepsy

经颅磁刺激作为早期抗癫痫药物开发中的转化生物标志物:一项在全身性癫痫中的随机、双盲、安慰剂对照研究

2026-05-010
OAAI
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial

实验性eIF2B激活剂DNL343在TDP-43病理学的临床前模型和随机临床试验中的ALS患者中调节整合应激反应

2025-08-180
OAAI
Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
2024-12-091
OAAI
The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis
2024-03-206
PRE
Administration of oxathridine, a first-in-class histamine-3 receptor partial agonist in healthy male volunteers: Central nervous system depression and pseudo-hallucinations
2023-10-110
PRE
The Integrated Stress Response Is Modulated by eIF2B Agonist DNL343: Results From Phase 1 Healthy Subject and Phase 1b ALS Patient Studies
2023-04-253
PRE
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease
2023-02-1831
OAAI
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients

新型RIPK1抑制剂SAR443060 (DNL747) 治疗神经退行性疾病的安全性,药代动力学和靶标参与: 健康受试者和患者的随机,安慰剂对照,双盲I/Ib期研究

2022-06-0140
OA